Fast Track is a procedural milestone that does not change the binary risk profile of Phase 3 development. Monitor for Phase 1 data updates and the start of pivotal trials in 2027 as the next catalysts.
Price Chart
Executive Summary
Vir Biotechnology announced that the FDA granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager for late-line metastatic castration-resistant prostate cancer, co-developed with Astellas. This is a modest regulatory milestone for a Phase 1 asset, providing potential for expedited review but no change to the binary risk of Phase 3 outcomes.
Key Facts
- FDA granted Fast Track designation to VIR-5500 for late-line mCRPC on October 8, 2026.
- VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager co-developed with Astellas Pharma Inc.
- Phase 1 study is ongoing across six dose-expansion cohorts; Phase 3 trials anticipated to begin in 2027.
- Phase 1 data reported earlier this year showed VIR-5500 was generally well tolerated with promising anti-tumor activity.
Financial Impact
No financial figures disclosed; Fast Track designation does not directly impact revenue or costs.
Risk Factors
- Phase 3 trials may fail to meet efficacy or safety endpoints.
- Competition from approved PSMA-targeted therapies (e.g., Pluvicto) and other T-cell engagers in development.
- Clinical development delays or regulatory setbacks could impair timelines.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-065408 |
| Document: a2026-10x01_8xkxvirx5500fa.htm | 0001628280-26-065408 |
| Document: 0001628280-26-065408-index-headers.html | 0001628280-26-065408 |
| Document: 0001628280-26-065408-index.html | 0001628280-26-065408 |
| Document: 0001628280-26-065408.txt | 0001628280-26-065408 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 8-K | $10.41 $10.57 | ▲ +1.54% | ▲ +1.08% | $10.95 (+5.19%) |
Oct 8, 2026 18d ago | 8-K | $11.12 $10.47 | ▼ −5.85% | ▼ −5.57% | $10.95 (−1.53%) |
Oct 6, 2026 19d ago | 3 | $11.60 $10.61 | ▼ −8.53% | ▼ −8.40% | $10.95 (−5.60%) |
Oct 1, 2026 25d ago | 8-K | $11.29 $11.12 | ▼ −1.51% | ▼ −2.81% | $10.95 (−3.01%) |
Sep 23, 2026 4w ago | Court Ruling | $10.72 $11.29 | ▲ +5.32% | ▲ +5.73% | $10.95 (+2.15%) |
Aug 14, 2026 10w ago | Court Ruling | $9.39 $9.91 | ▲ +5.54% | ▲ +6.73% | $10.95 (+16.61%) |
Aug 9, 2026 11w ago | Institutional Cluster | $8.89 $9.39 | ▲ +5.62% | ▲ +5.67% | $10.95 (+23.17%) |
Jul 24, 2026 13w ago | 8-K | $8.69 $8.90 | ▲ +2.42% | ▲ +2.04% | $10.95 (+26.01%) |
Jun 29, 2026 16w ago | 144 | $10.38 $10.02 | ▼ −3.47% | ▼ −4.86% | $10.95 (+5.49%) |
Jun 10, 2026 19w ago | 3 | $8.52 $9.30 | ▲ +9.15% | ▲ +8.72% | $10.95 (+28.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers